CN102170903B - 用于刺激免疫反应的产品和方法 - Google Patents

用于刺激免疫反应的产品和方法 Download PDF

Info

Publication number
CN102170903B
CN102170903B CN200980125581.9A CN200980125581A CN102170903B CN 102170903 B CN102170903 B CN 102170903B CN 200980125581 A CN200980125581 A CN 200980125581A CN 102170903 B CN102170903 B CN 102170903B
Authority
CN
China
Prior art keywords
cells
antigen
specific
bcr
hel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980125581.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102170903A (zh
Inventor
法存多·巴蒂斯塔
尤利娅·埃克尔-多尔纳
帕特里西亚·巴拉尔
温琴佐·塞伦多罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of CN102170903A publication Critical patent/CN102170903A/zh
Application granted granted Critical
Publication of CN102170903B publication Critical patent/CN102170903B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN200980125581.9A 2008-05-02 2009-05-05 用于刺激免疫反应的产品和方法 Expired - Fee Related CN102170903B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4981408P 2008-05-02 2008-05-02
US61/049,814 2008-05-02
PCT/GB2009/001111 WO2009133378A2 (en) 2008-05-02 2009-05-05 Products and methods for stimulating an immune response

Publications (2)

Publication Number Publication Date
CN102170903A CN102170903A (zh) 2011-08-31
CN102170903B true CN102170903B (zh) 2016-04-06

Family

ID=40888253

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980125581.9A Expired - Fee Related CN102170903B (zh) 2008-05-02 2009-05-05 用于刺激免疫反应的产品和方法

Country Status (8)

Country Link
US (1) US20110280930A1 (https=)
EP (3) EP2288381A2 (https=)
JP (3) JP5721620B2 (https=)
CN (1) CN102170903B (https=)
AU (1) AU2009241645B2 (https=)
CA (1) CA2723226A1 (https=)
ES (1) ES2570973T3 (https=)
WO (1) WO2009133378A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5721620B2 (ja) * 2008-05-02 2015-05-20 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ 免疫応答を刺激するための作製物および方法
US20140050780A1 (en) 2010-12-23 2014-02-20 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
CN103857387B (zh) 2011-06-02 2017-03-15 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法
TW201442739A (zh) * 2013-02-27 2014-11-16 Riken 過敏疾病治療藥
GB2514591A (en) 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
WO2015021390A2 (en) 2013-08-08 2015-02-12 The Regents Of The University Of California Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
WO2015084677A1 (en) * 2013-12-02 2015-06-11 Arytha Biosciences, Llc Toxoid preparation and uses thereof
WO2015143295A2 (en) 2014-03-20 2015-09-24 The Regents Of The University Of California Hydrogel compositions containing toxin-absorbing or binding nanoparticles and uses thereof
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
AU2015269412B2 (en) * 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016164705A1 (en) * 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
CN107530285B (zh) 2015-04-29 2021-07-27 加利福尼亚大学董事会 使用纳米粒子解毒
JP2018516996A (ja) * 2015-06-10 2018-06-28 ウニヴェルズィテート・デ・ザールラントＵｎｉｖｅｒｓｉｔａｅｔ Ｄｅｓ Ｓａａｒｌａｎｄｅｓ Ｂ細胞悪性腫瘍を処置するための手段および方法
EP3411475B1 (en) 2016-02-06 2025-08-27 President and Fellows of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
WO2017211314A1 (en) 2016-06-08 2017-12-14 Kei International Limited Method for detecting presence of mycobacterial material in sample using immobilised mannosyl phosphoketide antigen
NL2017204B1 (en) * 2016-06-08 2017-12-18 Kei International Ltd Solid substrate comprising antigens immobilised thereto, biosensor comprising said solid substrate and method for detecting the presence of mycobacterial material in a sample
CN115404196A (zh) 2016-07-13 2022-11-29 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
CN110418651A (zh) 2016-08-02 2019-11-05 哈佛学院院长等 用于调节免疫应答的生物材料
AU2017313806B2 (en) * 2016-08-17 2023-07-20 Orbis Health Solutions Llc Tumor-targeting bead vectors and methods of using the same
WO2019032862A1 (en) * 2017-08-10 2019-02-14 Dana-Farber Cancer Institute, Inc. CELLS EXPRESSING LMP1 AND METHODS OF USE
NL2021443B1 (en) 2018-08-08 2020-02-20 Kei International Ltd Synthetic antigens for tuberculosis detection
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
EP3650466A1 (en) * 2018-11-12 2020-05-13 Consejo Superior De Investigaciones Científicas In vitro production of high affinity monoclonal antibodies
CN111229023B (zh) * 2018-11-29 2022-01-28 内蒙古东盛硅藻土科技创新产业园有限公司 一种化学降解添加剂
WO2021061837A1 (en) 2019-09-23 2021-04-01 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof
CN112300987B (zh) * 2020-10-16 2022-04-29 中国农业大学 单个浆细胞的筛选方法及其在小分子单克隆抗体制备中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
AU7058691A (en) 1989-12-22 1991-07-24 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologically active proteines from borrelia burgdorferi, related test kits and vaccine
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0571538T5 (da) 1991-02-15 2002-03-04 Uab Research Foundation Strukturgen for pneumokokprotein
JPH07501687A (ja) 1991-08-15 1995-02-23 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） ボレリア・ブルグドルフェリのサブグループのｏｓｐ　ａ　蛋白、それをコードしている遺伝子およびワクチン
AU2903892A (en) 1991-10-22 1993-05-21 Symbicom Aktiebolag Improvement in (borrelia burgdorferi) diagnosis and prophylaxis
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6004763A (en) * 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
CA2196311A1 (en) 1994-08-19 1996-02-29 David H. Sachs Genetically engineered swine cells
CN1561389A (zh) 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
DE10164309A1 (de) * 2001-12-28 2003-07-10 Fraunhofer Ges Forschung Verbesserte strukturiert-funktionale Bindematrices für Biomoleküle
CA2494971A1 (en) * 2002-08-14 2004-02-26 Avidis Sa Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
AU2004311630A1 (en) * 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
ES2389080T3 (es) 2004-06-11 2012-10-23 Riken Fármaco que presenta un ligando de células reguladoras contenido en el liposoma
CN1980638B (zh) * 2004-07-07 2011-10-12 国立血清研究所 用糖脂稳定基于脂质的佐剂制剂的组合物和方法
US9079765B2 (en) * 2004-10-01 2015-07-14 Midatech Ltd. Nanoparticles comprising antigens and adjuvants, and immunogenic structures
AU2006219717B2 (en) * 2005-03-02 2009-05-21 The Secretary Of State For Defence Pharmaceutical composition
EP1945651B1 (en) 2005-10-25 2014-06-25 The Ludwig Institute for Cancer Research Analogs of alpha galactosylceramide and uses thereof
WO2007051004A2 (en) 2005-10-28 2007-05-03 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
US20070231344A1 (en) 2005-10-28 2007-10-04 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
JP5721620B2 (ja) * 2008-05-02 2015-05-20 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ 免疫応答を刺激するための作製物および方法
JP5782775B2 (ja) 2011-03-29 2015-09-24 ソニー株式会社 情報表示装置および情報表示方法、並びにプログラム

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B CELLS EXTRACT AND PRESENT IMMOBILIZATION ANTIGEN: IMPLICATIONS FOR AFFINITY DISCRIMINATION;BATISTA F D ET AL;《EMBO JOURNAL》;20000130;第19卷(第4期);第513-520页 *
Effect of different hapten-carrier conjugation ratios and molecular orientations on antibody affinity against a peptide antigen;PEDERSEN M K ET AL;《JOURNAL OF IMMUNOLOGICAL METHODS》;20060420;第311卷(第1-2期);第198-206页 *
Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma;PAUL NEESON ET AL;《CANCER IMMUNOLOGY, IMMUNOTHERAPY》;20070918;第57卷(第4期);第493-505页 *
Multivalent compounds for antigen-specific B cell tolerance and treatment of autoimmune diseases.;JONES DAVID S;《CURRENT MEDICINAL CHEMISTRY 2005》;20051231;第12卷(第16期);第1887-1904页 *

Also Published As

Publication number Publication date
EP2711021A1 (en) 2014-03-26
EP2711020A1 (en) 2014-03-26
EP2711021B1 (en) 2016-03-09
CA2723226A1 (en) 2009-05-11
ES2570973T3 (es) 2016-05-23
WO2009133378A3 (en) 2009-12-23
WO2009133378A2 (en) 2009-11-05
JP2011519847A (ja) 2011-07-14
JP2015038066A (ja) 2015-02-26
JP2015028023A (ja) 2015-02-12
US20110280930A1 (en) 2011-11-17
AU2009241645A1 (en) 2009-11-05
HK1190942A1 (en) 2014-07-18
CN102170903A (zh) 2011-08-31
EP2288381A2 (en) 2011-03-02
AU2009241645B2 (en) 2014-07-17
HK1191548A1 (en) 2014-08-01
HK1161542A1 (zh) 2012-07-27
JP5721620B2 (ja) 2015-05-20
JP5853068B2 (ja) 2016-02-09
EP2711020B1 (en) 2016-08-10

Similar Documents

Publication Publication Date Title
CN102170903B (zh) 用于刺激免疫反应的产品和方法
Pedersen et al. Vaccine adjuvants differentially affect kinetics of antibody and germinal center responses
US9950025B2 (en) Compositions and methods for treatment of neoplastic disease
BRPI0616770A2 (pt) modulação de respostas imunes mediadas por tlr empregando oligonucleotìdeos adaptadores
WO2022212564A1 (en) Targeting multiple t cell types using spherical nucleic acid vaccine architecture
US20180037650A1 (en) Pain Treatment
CN103608032A (zh) 用于抑制免疫应答的方法
WO2024086799A2 (en) Lipid nanoparticles and methods of using the same for treating cell proliferative diseases and disorders
AU2014250631B2 (en) Products and methods for stimulating an immune response
HK1161542B (en) Products and methods for stimulating an immune response
US20210015914A1 (en) Methods and compositions related to accelerated humoral affinity
HK1190942B (en) Products and methods for stimulating an immune response
HK1191548B (en) Products and methods for stimulating an immune response
Belcher et al. A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity
HK1191562A (en) Method for suppressing an immune response

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1161542

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20151016

Address after: English Marlowe

Applicant after: Cancer Rec Tech Ltd.

Address before: London, England

Applicant before: Cancer Rec Tech Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160406

Termination date: 20170505

CF01 Termination of patent right due to non-payment of annual fee